Skip to content
10-Q

Quarterly Report

Viracta Therapeutics, Inc.

0000950170-24-057250

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 6, 2024 39.27M sh
Shares Diluted Q1 2024 · Mar 31, 2024 39.32M sh
Shares Diluted Q1 2024 · Mar 31, 2023 38.46M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$7.85M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$11.34M
Short Term Debt Q1 2024 · Mar 31, 2024 $18.68M
Short Term Debt Q1 2024 · Dec 31, 2023 $25.27M
Short Term Investments Q1 2024 · Mar 31, 2024 $27.5M
Short Term Investments Q1 2024 · Dec 31, 2023 $41.37M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $12.06M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $12.32M
Stockholders Equity Q1 2024 · Mar 31, 2024 $11.08M
Stockholders Equity Q1 2024 · Dec 31, 2023 $18.32M
Stockholders Equity Q1 2024 · Mar 31, 2023 $51.11M
Stockholders Equity Q1 2024 · Dec 31, 2022 $61.1M
Current Liabilities Q1 2024 · Mar 31, 2024 $30.25M
Current Liabilities Q1 2024 · Dec 31, 2023 $38.37M
Total Liabilities Q1 2024 · Mar 31, 2024 $30.25M
Total Liabilities Q1 2024 · Dec 31, 2023 $38.37M
Current Assets Q1 2024 · Mar 31, 2024 $40.95M
Current Assets Q1 2024 · Dec 31, 2023 $54.96M
Total Assets Q1 2024 · Mar 31, 2024 $41.33M
Total Assets Q1 2024 · Dec 31, 2023 $56.69M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.23
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.32
Eps Basic Q1 2024 · Mar 31, 2024 −$0.23
Eps Basic Q1 2024 · Mar 31, 2023 −$0.32
Sga Expense Q1 2024 · Mar 31, 2024 $3.92M
Sga Expense Q1 2024 · Mar 31, 2023 $4.6M
Net Income Q1 2024 · Mar 31, 2024 −$9.14M
Net Income Q1 2024 · Mar 31, 2023 −$12.21M
Operating Income Q1 2024 · Mar 31, 2024 −$13.88M
Operating Income Q1 2024 · Mar 31, 2023 −$12.21M